Argenx
Willemstraat 5
Breda
4811 AH
Tel: 31-0-10-763-030-488
Website: http://www.argenx.com/
Email: nfo@argenx.com
About Argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.YEAR FOUNDED:
2008
LEADERSHIP:
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
JOBS:
Please click here for Argenx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
69 articles with Argenx
-
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
2/4/2019
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn
-
Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
12/3/2018
Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain
-
Regulated information – Inside information argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
12/3/2018
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110)
-
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
12/3/2018
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)
-
Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
-
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
-
Argenx Announces Closing of U.S. Public Offering for Gross Proceeds of Approximately $26M
12/19/2017
Argenx announced today the closing of its public offering in the United States of 5,106,000 ADSs, at a price of $52.00 per ADS, for gross proceeds of approximately $266M.
-
argenx Bags $231M in Upsized U.S. IPO
12/14/2017
argenx increased the Offering from the initially filed offering size of $150 million. -
argenx Announces Size of Proposed Public Offering in the United States Updated to 3.5 Million ADSs
12/13/2017
All of the ADSs in the proposed Offering are to be sold by argenx.
-
argenx Announces Launch of Proposed Public Offering in the United States
12/12/2017
Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx.
-
argenx to Provide Updates on Phase I/II Clinical Trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma During American Society of Hematology Annual Meeting
12/11/2017
The workshop will be held Monday, December 11th at 12:00 pm EST.
-
argenx Reports Positive Topline Results From Phase II Proof-of-Concept Trial of ARGX-113 (Efgartigimod) in Generalized Myasthenia Gravis
12/11/2017
Favorable tolerability profile consistent with Phase 1 data.
-
argenx Announces Results of Extraordinary Shareholders' Meeting 2017
11/7/2017
All proposed resolutions on the agenda for this extraordinary shareholders' meeting were approved.
-
Argenx to Host KOL Breakfast Symposium on Pemphigus Vulgaris on November 10, 2017
11/2/2017
The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV.
-
argenx Launches Phase I trial With Subcutaneous Formulation of ARGX-113
10/30/2017
The first subject has been dosed in the Phase I clinical trial.
-
Argenx Reports Third Quarter 2017 Financial Results and Provides Business Update
10/26/2017
The company announced financial results and provided a business update for the third quarter ended September 30, 2017.
-
Argenx Launches Phase II Proof-Of-Concept Clinical Trial Of ARGX-113 For The Treatment Of Pemphigus Vulgaris
9/26/2017